41 results about "Cyclopamine" patented technology

The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of the present invention are particularly useful in treating cancers.

The invention provides novel derivatives of cyclopamine having the following formula:

This invention concerns the use of cyclopamine in vivo on basal cell carcinomas (BCC's) to achieve therapeutic effect by causing differentiation of the tumor cells and, at the same time, apoptotic death and removal of these tumor cells while preserving the normal tissue cells, including the undifferentiated cells of the normal epidermal basal layer and hair follicles. Causation of apoptosis by cyclopamine is by a non-genotoxic mechanism and thus unlike the radiation therapy and most of the currently used cancer chemotherapeutics which act by causing DNA-damage. These novel effects, previously unachieved by a cancer chemotherapeutic, make the use of cyclopamine highly desirable in cancer therapy, in the treatment of BCC's and other tumors that use the hedgehog / smoothened signal transduction pathway for proliferation and prevention of apoptosis.

Cyclopamine or a similarly specific inhibitor of Hedgehog / Smoothened (Hh / Smo) signaling can be used for obtaining decrease of pigmentation of hyperpigmented skin areas.

The present invention relates to steroidal alkaloids useful in the treatment of hedgehog pathway related disorders, particularly cancer.

The present disclosure relates generally to methods of treating hematopoietic cell malignancy in a subject by administering to the subject a Hedgehog (Hh) pathway antagonist, such as a Smoothen (Smo) antagonist alone or in combination with an ABL-kinase antagonist. Specifically, the disclosure relates to a method of treating hematopoietic cell malignancy in a subject by administering the Hh pathway antagonist, such as the Smo antagonist cyclopamine, in combination with the ABL-kinase antagonist imatinib.

The invention provides biocompatible micelles loaded with one or more active agents. The micelles can encapsulate anticancer drugs such as gossypol, and combinations of drugs, such as gossypol and paclitaxel, gossypol and 17-AAG, gossypol and cyclopamine, gossypol, paclitaxel, and 17-AAG, and gossypol, paclitaxel, and cyclopamine. The micelle compositions provide effective solubilization of difficult to solubilize drug combinations without the need for additional surfactants that can be toxic to patients. Thus, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity.

This invention concerns the use of cyclopamine in vivo on basal cell carcinomas (BCC's) to achieve therapeutic effect by causing differentiation of the tumor cells and, at the same time, apoptotic death and removal of these tumor cells while preserving the normal tissue cells, including the undifferentiated cells of the normal epidermal basal layer and hair follicles. Causation of apoptosis by cyclopamine is by a non-genotoxic mechanism and thus unlike the radiation therapy and most of the currently used cancer chemotherapeutics which act by causing DNA-damage. These novel effects, previously unachieved by a cancer chemotherapeutic, make the use of cyclopamine highly desirable in cancer therapy, in the treatment of BCC's and other tumors that use the hedgehog / smoothened signal transduction pathway for proliferation and prevention of apoptosis.

The present invention relates to steroid-derived cyclopamine analogs and methods for using the same for inhibiting sonic hedgehog signaling and preventing or treating cancer. A method for synthesizing the analogs of the present invention from a steroid is also provided.

The invention relates to the technical field of biology, in particular to Shh pathway regulation and control biological rhythm and related application thereof. Specifically, the invention provides application of a Hedgehog pathway inhibitor and an SMO inhibitor in regulating the biological rhythm and treating diseases related to the biological rhythm. Preferably, the Hedgehog pathway inhibitor comprises the following components: PF-5274857, Mebendazole, HPI-4, SANT-1, Taladegib, Grasdegib, Cyclopamine, Itracazole, GANT61, JK184, Robotnikinin, Vismodegib, Purmorphamine, and Sonidegib Phoshate, and the Hedgehog pathway inhibitor comprises the following components: PF-5274857, the Mebendazole, the HPI-4, the SANT-1, the Taladegib, the Grasdegib, the Cyclopamine, the Itracazole, the GANT61, the JK184, the Robotnikinin, the Vismodegib, the

The invention discloses a respiratory syncytial virus infection treating compound and a preparation method and application thereof. The compound refers to chemical analogues of cyclopamine and is characterized by suppressing replication of respiratory syncytial virus without suppressing Hedgehog signal pathway. The preparation method includes synthesizing the chemical analogues of cyclopamine in a medicinal chemistry way and then screening the analogues by means of in-vitro tests performed in parallel. The compound is applied to treatment of respiratory virus infection, paramyxovirus infection, respiratory syncytial virus infection, and capillary bronchitis, pneumonia and tympanitis which are all caused by respiratory syncytial virus, is free of toxic and side effect to cause fetal anomaly, overcomes teratogenicity of cyclopamine, and fills the blank of drugs especially pediatric drugs for treating respiratory syncytial virus infection.

The present invention relates to steroid-derived cyclopamine analogs and methods for using the same for inhibiting sonic hedgehog signaling and preventing or treating cancer. A method for synthesizing the analogs of the present invention from a steroid is also provided.

The present invention relates to steroidal alkaloid-like compounds useful in the treatment of diseases associated with the hedgehog pathway, especially cancer.

The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides highly water-soluble analogs of cyclopamine that are potent, hedgehog signaling inhibitors less toxic than cyclopamine. The compounds of the present invention are particularly useful in treating cancers associated with hedgehog signalling.

The invention discloses a compound for treating respiratory syncytial virus infection, a preparation method and application thereof. The compound is a chemical analogue of cyclopamine, which has the property of inhibiting the replication of respiratory syncytial virus, but does not have the property of inhibiting Hedgehog signaling pathway. The preparation method synthesizes the chemical analogs of the cyclopamine through pharmaceutical chemistry, and screens the analogs through two parallel in vitro tests. The compound can be used to treat respiratory virus infection, paramyxovirus infection, respiratory syncytial virus infection, bronchiolitis caused by respiratory syncytial virus, pneumonia caused by respiratory syncytial virus, otitis media caused by respiratory syncytial virus, It does not have the toxic and side effects of causing fetal malformation, overcomes the teratogenic properties of cyclopamine, and fills in the blank of drugs for treating respiratory syncytial virus infection, especially pediatric drugs.